Search

Your search keyword '"Arthritis -- Drug therapy"' showing total 2,226 results
Start Over Descriptor "Arthritis -- Drug therapy"
2,226 results on '"Arthritis -- Drug therapy"'

52. Celon Pharma Announces Results of Phase II clinical trial for CPL' 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)

Subjects
Rheumatoid factor, Antirheumatic agents -- Product development, Arthritis -- Drug therapy, Clinical trials, Banking, finance and accounting industries, Business
Abstract

KIELPIN, Poland, June 17, 2024 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of [...]

Published
2024

53. Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Health aspects, Autoimmunity -- Health aspects, B cells -- Health aspects, Arthritis -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in [...]

Published
2024

54. Kevzara(r) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Subjects
United States. Food and Drug Administration, Regeneron Pharmaceuticals Inc., Sanofi S.A., Antiarthritic agents, Arthritis -- Drug therapy, Monoclonal antibodies, Pharmaceutical industry, General interest, News, opinion and commentary, Kevzara (Medication)
Abstract

TARRYTOWN: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara(r) (sarilumab) for the treatment of patients weighing 63 kg or [...]

Published
2024

55. Kevzara(R) (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Subjects
United States. Food and Drug Administration, Regeneron Pharmaceuticals Inc., Sanofi S.A., Children -- Diseases, Rheumatoid factor, Governmental investigations, Arthritis -- Drug therapy, Drug approval, Pharmaceutical industry, Banking, finance and accounting industries, Business, Kevzara (Medication)
Abstract

Approval in patients with pJIA weighing 63kg or greater adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, [...]

Published
2024

56. SecondWave Systems Demonstrates Reduction in Disease Activity in Clinical Study Evaluating Novel Ultrasound-Based Anti-Inflammatory Therapy in Rheumatoid Arthritis

Subjects
Medical research, Medicine, Experimental, Rheumatoid factor, Antiarthritic agents, Arthritis -- Drug therapy, Clinical trials, Anti-inflammatory drugs, Business, Business, international
Abstract

Study marks the first demonstration of novel splenic ultrasound therapy to significantly reduce rheumatoid arthritis disease activity ST. PAUL, Minn. -- SecondWave Systems, Inc., a pioneer in the emerging field [...]

Published
2024

57. Strictly Come Dancing star in tears as he tells fans 'I hate who I become'; Adam Thomas has been taking medication for rheumatoid arthritis and has told fans how it has left him in tears

Subjects
Rheumatoid factor, Antiarthritic agents, Arthritis -- Drug therapy, General interest, News, opinion and commentary
Abstract

Byline: By, Elaine Blackburne & LeicestershireLive Reporter Strictly Come Dancing star Adam Thomas has opened up about his struggle with rheumatoid arthritis medication, revealing it often leaves him in tears. [...]

Published
2024

59. Purified Cortrophin Gel Available in New Vial Size

Author

Park, Brian

Subjects
Psoriasis -- Drug therapy, Rheumatoid factor, Atopic dermatitis -- Drug therapy, Arthritis -- Drug therapy, Health
Abstract

Purified Cortrophin[sup.®] Gel (repository corticotropin injection USP) is now available in a 1mL multiple-dose vial (80 USP units/1mL), in addition to the 5mL multiple-dose vial (80 USP units/1mL). https://www.empr.com/drug/purified-cortrophin-gel/ is [...]

Published
2023

60. Research and Markets Releases Report: Global Rheumatoid Arthritis Drugs Market

Subjects
Rheumatoid factor -- Reports -- Forecasts and trends, Antiarthritic agents -- Reports -- Forecasts and trends, Arthritis -- Drug therapy, Market trend/market analysis, Food and beverage industries
Abstract

The 'Rheumatoid Arthritis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis' report has been added to ResearchAndMarkets.com's offering. According to a release, [...]

Published
2023

61. Prevalence of Arthritis 305 Per 100,000 Children, Teens in US

Subjects
Arthritis -- Drug therapy, African Americans -- Health aspects -- Reports, Health
Abstract

HealthDay News — The prevalence of arthritis is 305 per 100,000 children and adolescents in the US, with higher prevalence among non-Hispanic Black or African American vs non-Hispanic White children [...]

Published
2023

62. Arnicare Product Line Expands With New Homeopathic Arthritis Cream

Author

Ernst, Diana

Subjects
Antiarthritic agents, Homeopathy -- Materia medica and therapeutics, Arthritis -- Drug therapy, Health
Abstract

Arnicare Arthritis Cream is now available over-the-counter (OTC) for the temporary relief of minor joint pain, muscle pain, and stiffness due to arthritis for individuals aged 12 years and older. [...]

Published
2023

63. Yuflyma, a Citrate-Free, High-Concentration Biosimilar to Humira, Gets FDA Approval

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Psoriasis -- Drug therapy, Rheumatoid factor, Arthritis -- Drug therapy, Adalimumab, Drug approval, Tumor necrosis factor, Health, Humira (Medication)
Abstract

The Food and Drug Administration (FDA) has approved Yuflyma[sup.®] (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free biosimilar to Humira[sup.®] (adalimumab). Yuflymais a tumor necrosis factor indicated for: * Rheumatoid arthritis (RA): [...]

Published
2023

64. Biosimilar Cyltezo Soon to Be Available in Prefilled Pen

Author

Ernst, Diana

Subjects
Psoriasis -- Drug therapy, Arthritis -- Drug therapy, Tumor necrosis factor, Health, Cyltezo (Medication)
Abstract

Cyltezo[sup.®] (adalimumab-adbm), an https://www.empr.com/home/news/first-interchangeable-biosimilar-to-humira-gets-fda-approval/ (adalimumab), will soon be available in a new autoinjector device, in addition to the prefilled syringe. Cyltezo is a tumor necrosis factor (TNF) blocker approved for [...]

Published
2023

65. Peresolimab Found to Be Efficacious for Rheumatoid Arthritis

Subjects
Eli Lilly and Co. -- Reports, Rheumatoid factor -- Reports, Antirheumatic agents -- Reports, Arthritis -- Drug therapy, Apoptosis -- Reports, Monoclonal antibodies -- Reports, Health
Abstract

HealthDay News — Peresolimab, a humanized immunoglobulin G1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway, is efficacious for patients with rheumatoid arthritis, [...]

Published
2023

66. SecondWave Systems Announces Professor Paul Peter Tak as New Advisory Board Member and Secures $3M Additional Financing to Accelerate Development of Novel Ultrasound-Based Anti-Inflammatory Therapy

Subjects
United States. Defense Advanced Research Projects Agency -- Technology application, Medical centers -- Technology application, Rheumatoid factor -- Technology application, Antiarthritic agents -- Technology application, Arthritis -- Drug therapy, Anti-inflammatory drugs -- Technology application, Technology application, Business, Business, international
Abstract

New funding from ARPA-H, in partnership with DARPA, directly supports development of next-generation technology for at-home treatment of rheumatoid arthritis and other inflammatory disorders ST. PAUL, Minn. -- SecondWave Systems, [...]

Published
2024

67. Rheumatoid Arthritis Drugs Market Size to Worth USD 27.38 Bn by 2033

Subjects
Rheumatoid factor, Antiarthritic agents, Health care industry, Arthritis -- Drug therapy, Health care industry, General interest, News, opinion and commentary
Abstract

Ottawa: Precedence Research has issued the following news release: The global rheumatoid arthritis drugs market size was valued at USD 17.87 billion in 2023 and is projected to reach around [...]

Published
2024

68. Rheumatoid Arthritis Drugs Market Size to Worth USD 27.38 Bn by 2033

Subjects
Rheumatoid factor, Antiarthritic agents, Health care industry, Arthritis -- Drug therapy, Health care industry, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - The global rheumatoid arthritis drugs market size was valued at USD 17.87 billion in 2023 and is projected to reach around USD 25.67 billion by 2032, a study [...]

Published
2024

69. Advanced Arthritis Treatment Options Unveiled by San Jose's Top Specialist, Scott Lamb

Subjects
Antiarthritic agents, Arthritis -- Drug therapy, Business, Business, international
Abstract

M2 PRESSWIRE-March 12, 2024-: Advanced Arthritis Treatment Options Unveiled by San Jose's Top Specialist, Scott Lamb (C)1994-2024 M2 COMMUNICATIONS RDATE:12032024 In San Jose, individuals grappling with arthritis have a reliable [...]

Published
2024

70. Alvotech and Teva Announce U.S. Approval of SIMLANDI(r) (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira(r)

Subjects
United States. Food and Drug Administration, Teva Pharmaceutical Industries Ltd., Psoriasis -- Drug therapy, Rheumatoid factor, Arthritis -- Drug therapy, Adalimumab, Pharmaceutical industry, Business, international, Humira (Medication)
Abstract

Helsinki: Alvotech S.A. has issued the following news release: Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that [...]

Published
2024

71. Clinical trial shows rheumatoid arthritis drug could prevent disease

Subjects
Rheumatoid factor, Antirheumatic agents -- Product development, Arthritis -- Drug therapy, Clinical trials, Business, international
Abstract

London: King's College London has issued the following news release: A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk. Results [...]

Published
2024

72. Drug Used to Treat Rheumatoid Arthritis May Also Help Prevent It

Subjects
Rheumatoid factor, Antiarthritic agents, Arthritis -- Drug therapy, Health
Abstract

Byline: Dennis Thompson HealthDay Reporter THURSDAY, Feb. 15, 2024 (HealthDay News) -- Philip Day loved playing soccer so much that the 35-year-old software engineer founded a website - FootballMatcher.com - [...]

Published
2024

74. New Findings Reported from Sri Guru Ram Das Institute of Medical Sciences and Research Describe Advances in Rheumatoid Arthritis (Drug-induced Accelerated Nodulosis In a Patient With Rheumatoid Arthritis)

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Rheumatoid factor -- Reports, Immunotherapy -- Reports, Arthritis -- Drug therapy, Methotrexate -- Reports, Health
Abstract

2024 JUL 10 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on Autoimmune Diseases and Conditions - Rheumatoid Arthritis are discussed in a new [...]

Published
2024

75. Researchers from First School of Clinical Medicine Discuss Research in Rheumatoid Arthritis (Integrated analysis of single-cell RNA-seq, bulk RNA-seq, Mendelian randomization, and eQTL reveals T cell-related nomogram model and subtype ...)

Subjects
T cells, Rheumatoid factor, Antiarthritic agents, Immunotherapy, Arthritis -- Drug therapy, Health
Abstract

2024 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on rheumatoid arthritis have been presented. According to news originating from Nanning, People's [...]

Published
2024

76. First Affiliated Hospital of Jinan University Researchers Have Published New Data on Crohn's Disease (Identification of therapeutic targets and medicines for comorbid Crohn's disease and rheumatoid arthritis: A comprehensive analysis)

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Rheumatoid factor -- Analysis, Antiarthritic agents -- Analysis, Diseases -- Drug therapy, Comorbidity -- Drug therapy, Arthritis -- Drug therapy, Health
Abstract

2024 JUN 28 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Crohn's disease. According to news reporting from First [...]

Published
2024

77. Recent Studies from First Affiliated Hospital of Gannan Medical University Add New Data to Rheumatoid Arthritis (The protective effect of natural medicines in rheumatoid arthritis via inhibit angiogenesis)

Subjects
Rheumatoid factor, Antiarthritic agents, Arthritis -- Drug therapy, Health
Abstract

2024 JUN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on rheumatoid arthritis have been presented. According to news reporting from [...]

Published
2024

78. Regeneron: Kevzara (sarilumab) Approved by FDA for Treatment of

Subjects
United States. Food and Drug Administration, Regeneron Pharmaceuticals Inc., Sanofi S.A., Antiarthritic agents, Arthritis -- Drug therapy, Drug approval, Pharmaceutical industry, Business, Business, international, Telecommunications industry, Kevzara (Medication)
Abstract

Regeneron Pharmaceuticals and Sanofi reported that the U.S. Food and Drug Administration has approved Kevzara (sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile [...]

Published
2024

79. Researchers at SVKM's Dr. Bhanuben Nanavati College of Pharmacy Release New Data on Rheumatoid Arthritis (Exploring the therapeutic opportunities of potassium channels for the treatment of rheumatoid arthritis)

Subjects
Rheumatoid factor, Potassium channels, Antiarthritic agents, Arthritis -- Drug therapy, Pharmacy, Health
Abstract

2024 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on rheumatoid arthritis is the subject of a new report. According [...]

Published
2024

80. Teva and Alvotech launch SIMLANDI biosimilar in the US

Subjects
Teva Pharmaceutical Industries Ltd., Psoriasis -- Drug therapy, Rheumatoid factor, Arthritis -- Drug therapy, Adalimumab, Drug approval, Pharmaceutical industry, Business, Simlandi (Medication), Humira (Medication)
Abstract

M2 EQUITYBITES-May 21, 2024-Teva and Alvotech launch SIMLANDI biosimilar in the US (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biotech company Alvotech S.A. (NASDAQ:ALVO) and Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical [...]

Published
2024

81. Teva and Alvotech launch SIMLANDI biosimilar in the US

Subjects
Teva Pharmaceutical Industries Ltd., Psoriasis -- Drug therapy, Rheumatoid factor, Arthritis -- Drug therapy, Adalimumab, Drug approval, Pharmaceutical industry, Chemistry, Simlandi (Medication), Humira (Medication)
Abstract

M2 PHARMA-May 21, 2024-Teva and Alvotech launch SIMLANDI biosimilar in the US (C)2024 M2 COMMUNICATIONS Biotech company Alvotech S.A. (NASDAQ:ALVO) and Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company [...]

Published
2024

82. Department of Laboratory Medicine Researchers Describe Research in Rheumatoid Arthritis (Classification of rheumatoid arthritis: is it time to revise the criteria?)

Subjects
Medical research -- Analysis -- Reports, Medicine, Experimental -- Analysis -- Reports, Rheumatoid factor -- Reports -- Analysis, Antiarthritic agents -- Analysis -- Reports, Arthritis -- Drug therapy, Health, American College of Rheumatology -- Reports
Abstract

2024 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on rheumatoid arthritis. According to news reporting originating from [...]

Published
2024

83. Researcher from University of Maryland School of Medicine Reports on Findings in Cancer Gene Therapy (The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy)

Subjects
Genetic research -- Reports, Genes -- Reports, Antiarthritic agents -- Reports, Gene therapy -- Reports, Arthritis -- Drug therapy, Cancer -- Genetic aspects -- Research -- Drug therapy, Drug delivery systems -- Reports, Peptides -- Reports, Physical fitness -- Reports, Oncology, Experimental -- Reports, Drugs -- Vehicles, Health
Abstract

2023 APR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on cancer gene therapy are presented in a new report. [...]

Published
2023

84. Research Data from Nanjing University Update Understanding of Rheumatoid Arthritis (Ecm-inspired Hydrogels With Adscs Encapsulation for Rheumatoid Arthritis Treatment)

Subjects
Rheumatoid factor, Stem cells -- Transplantation, Antirheumatic agents, Arthritis -- Drug therapy, Health, Nanjing University
Abstract

2023 MAR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Fresh data on Autoimmune Diseases and Conditions - Rheumatoid Arthritis are presented in a [...]

Published
2023

85. Study Findings on Rheumatoid Arthritis Published by Researchers at Northwestern Polytechnical University (Macrophage-Targeted Dextran Sulfate-Dexamethasone Conjugate Micelles for Effective Treatment of Rheumatoid Arthritis)

Subjects
Dextran, Rheumatoid factor, Central nervous system depressants, Dexamethasone, Arthritis -- Drug therapy, Macrophages, Sulfates, Physical fitness, Health
Abstract

2023 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on rheumatoid arthritis have been published. According to news [...]

Published
2023

86. A large-scale Boolean model of the Rheumatoid Arthritis Fibroblast-Like Synoviocytes predicts drug synergies in the arthritic joint

Subjects
Rheumatoid factor -- Models, Antiarthritic agents -- Models, Arthritis -- Drug therapy, Apoptosis -- Models, Physical fitness -- Models, Health
Abstract

2023 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2023

87. Affiliated Hospital of Guizhou Medical University Researcher Describes New Findings in Rheumatoid Arthritis (Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis)

Subjects
Rheumatoid factor -- Analysis, Arthritis -- Drug therapy, Physical fitness -- Analysis, Health
Abstract

2023 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in rheumatoid arthritis. According to news originating from [...]

Published
2023

88. Department of Rheumatology Researchers Describe Recent Advances in Rheumatoid Arthritis (Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and ...)

Subjects
Medical research -- Comparative analysis -- Reports, Medicine, Experimental -- Comparative analysis -- Reports, Rheumatoid factor -- Comparative analysis -- Reports, Drugs -- Comparative analysis -- Reports, Antirheumatic agents -- Comparative analysis -- Reports, Arthritis -- Drug therapy, Physical fitness -- Comparative analysis -- Reports, Health
Abstract

2023 JAN 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on rheumatoid arthritis are discussed in a new report. According [...]

Published
2023

89. University of Kansas Medical Center Researchers Report Recent Findings in Arthritis (Metabolomic Profiling of Red Blood Cells to Identify Molecular Markers of Methotrexate Response in the Collagen Induced Arthritis Mouse Model)

Subjects
Genetic markers -- Identification and classification -- Health aspects, Erythrocytes -- Physiological aspects -- Health aspects -- Genetic aspects, Arthritis -- Drug therapy, Methotrexate -- Dosage and administration -- Physiological aspects, Health
Abstract

2023 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on arthritis have been published. According to news originating [...]

Published
2023

90. Researcher at University of Sydney Releases New Study Findings on Medical Marijuana (Medicinal cannabis for Australian patients with chronic refractory pain including arthritis)

Subjects
Medical marijuana -- Testing, Chronic pain -- Drug therapy, Arthritis -- Drug therapy, Health
Abstract

2023 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on medical marijuana. According to news originating from [...]

Published
2023

91. Huanghe Science and Technology College Researchers Discuss Findings in Rheumatoid Arthritis (Towards Better Sinomenine-Type Drugs to Treat Rheumatoid Arthritis: Molecular Mechanisms and Structural Modification)

Subjects
Rheumatoid factor, Antiarthritic agents, Technical institutes, Medicine, Botanic, Arthritis -- Drug therapy, Medicine, Herbal, Physical fitness, Health
Abstract

2023 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on rheumatoid arthritis have been presented. According to news reporting [...]

Published
2023

92. Idacio, a Citrate-Free Biosimilar to Humira, Gets FDA Approval

Author

Park, Brian

Subjects
Psoriasis -- Drug therapy, Rheumatoid factor, Arthritis -- Drug therapy, Tumor necrosis factor, Adalimumab, Drug approval, Health
Abstract

The Food and Drug Administration (FDA) has approved Idacio[sup.®] (adalimumab-aacf), a citrate-free biosimilar to https://www.empr.com/drug/humira/ [sup.®] (adalimumab). Idacio is a tumor necrosis factor indicated for: * Rheumatoid arthritis (RA): reducing [...]

Published
2022

93. Research from Future University in Egypt in the Area of Artificial Intelligence Published (Artificial intelligence-assisted development of in situ forming nanoparticles for arthritis therapy via intra-articular delivery)

Subjects
Nonsteroidal anti-inflammatory drugs -- Dosage and administration, Injections, Intra-articular -- Research, Artificial intelligence -- Usage -- Health aspects, Nanoparticles -- Design and construction -- Usage -- Health aspects, Arthritis -- Drug therapy, Pharmaceutical research, Artificial intelligence, Health
Abstract

2022 DEC 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on artificial intelligence is now available. According to news [...]

Published
2022

94. Data on Arthritis Detailed by Researchers at School of Mechanical Engineering (Carbon Nanotubes: an Optimistic Nanomaterial With Superfluity Characteristics In Drug Delivery for the Treatment of Arthritis)

Subjects
Drugs -- Vehicles, Arthritis -- Drug therapy, Nanotubes -- Health aspects, Drug delivery systems -- Testing, Health
Abstract

2022 DEC 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Musculoskeletal Diseases and Conditions - Arthritis have been [...]

Published
2022

95. One-Year Retention High With Infliximab Biosimilar Switching in Inflammatory Arthritis

Author

Duffy, Steve

Subjects
Infliximab, Rheumatoid factor, Arthritis -- Drug therapy, Health, American College of Rheumatology
Abstract

One-year retention following infliximab biosimilar-to-biosimilar switching among patients with inflammatory arthritis was found to be high, according to results of a real-world observational cohort study presented at the American College [...]

Published
2022

97. Rheumatoid Arthritis Drugs Market Size & Share to Surpass USD 29.3 billion by 2031 | Analysis by Transparency Market Research

Subjects
Rheumatoid factor -- Statistics, Antiarthritic agents -- Market research -- Statistics, Marketing research -- Statistics, Arthritis -- Drug therapy, Pharmacogenetics -- Statistics, Marketing research, General interest, News, opinion and commentary
Abstract

Wilmington: Transparency Market Research has issued the following press release: Transparency Market Research Inc. - The rheumatoid arthritis drugs market was valued at US$ 17.5 billion in 2022. The market [...]

Published
2024

98. Rheumatoid Arthritis Drugs Market Size & Share to Surpass USD 29.3 billion by 2031 | Analysis by Transparency Market Research

Subjects
Rheumatoid factor -- Forecasts and trends -- Statistics, Drugs -- Statistics -- Market research, Antirheumatic agents -- Statistics -- Market research, Marketing research -- Forecasts and trends -- Statistics, Arthritis -- Drug therapy, Pharmacogenetics -- Forecasts and trends -- Statistics, Marketing research, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Transparency Market Research Inc. - The rheumatoid arthritis drugs market was valued at US$ 17.5 billion in 2022. The market is predicted to grow at a CAGR of [...]

Published
2024

100. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis

Subjects
Rheumatoid factor, Antiarthritic agents, Information services industry, Arthritis -- Drug therapy, Information services, Information services industry, Business, Business, international
Abstract

M2 PRESSWIRE-December 21, 2023-: Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis (C)1994-2023 M2 COMMUNICATIONS RDATE:20122023 Relationship leverages Quest's sequencing and specimen [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results